Drug Shortages Proposal From Sen. Hatch Offers 7-Year Economic Incentives
The Utah Republican’s draft bill would provide higher reimbursement rates for sterile injectable products and provide exclusivity incentives. House Republicans continue to pursue economic options, but time and jurisdictional factors could work against such measures to address shortages.
You may also be interested in...
Drug Shortage Bill In House Refines Hatch Reimbursement Proposal
Sterile injectable products with three or fewer manufacturers would get better federal reimbursement rates in an effort to attract more producers to the market; H.R. 6611 was modeled after a similar proposal from Sen. Orrin Hatch, R-Utah.
Reimbursement Questions Add To Compounding Regulation Debate
Public Citizen asks whether CMS policy could have helped prevent the drug contamination at New England Compounding Center as Senate committee wants more information on states’ regulatory practices.
User Fee Bills: After Mark-ups, How Will House And Senate Reconcile Differences?
House and Senate committee user fee bill mark-ups approaching, but drafts have differences in drug shortage, supply chain security and other proposed policy changes to reconcile.